Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled time : 10:00 save search
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Published: 2024-04-09 (Crawled : 10:00) - prnewswire.com
BCLI | $0.54 5.0% 940K
|
Health Technology
|
| O: 10.45%
H: 0.0%
C: 0.0%
fda als cell for trial therapeutics agreement
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
Published: 2024-04-01 (Crawled : 10:00) - globenewswire.com
LQDA M | $13.485 -2.35% 160K
|
Health Technology
|
| O: 2.99%
H: 0.06%
C: -3.74%
fda approval favorable update potential
FDA approves Ligand's molluscum contagiosum treatment – Pharmaceutical Technology
Published: 2024-01-08 (Crawled : 10:00) - spacfeed.com
CPT 4 | $96.39 1.15% 290K
|
Finance
|
| O: -0.46%
H: 1.63%
C: 1.54%
molluscum fda treatment technology
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
Published: 2023-12-22 (Crawled : 10:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
fda pharma drug application
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
Published: 2023-10-18 (Crawled : 10:00) - prnewswire.com
BCLI | $0.54 5.0% 940K
|
Health Technology
|
| O: 5.0%
H: 0.53%
C: -2.86%
fda als cell nurown treatment therapeutics
Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
Published: 2023-08-30 (Crawled : 10:00) - globenewswire.com
OTLK P | $8.4 1.33% 94K
|
Health Technology
|
| O: -80.19%
H: 10.96%
C: -3.87%
ons-5010 therapeutics fda review update treatment
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 3.5%
H: 0.81%
C: -3.62%
skyclarys fda approval pharmaceuticals
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023
Published: 2023-06-06 (Crawled : 10:00) - prnewswire.com
BCLI | $0.54 5.0% 940K
|
Health Technology
|
| O: 6.4%
H: 5.7%
C: -5.06%
nurown fda license review cell meeting application therapeutics
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease
Published: 2023-05-10 (Crawled : 10:00) - prnewswire.com
PLX | $1.135 0.44% 340K
|
Health Services
|
| O: 3.42%
H: 2.65%
C: -2.65%
elfabrio fda rare disease approval treatment global
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
Published: 2023-05-08 (Crawled : 10:00) - globenewswire.com
IMRN | $2.36 -3.67% 20K
|
Health Technology
|
| O: 57.75%
H: 8.81%
C: -9.15%
fda trial
Spectral MD Holdings, Ltd., an FDA Breakthrough Designated … – PharmiWeb.com
Published: 2023-04-11 (Crawled : 10:00) - spacfeed.com
DMYS | $10.25 0.0% 54K
|
n/a
| Email alert
Add to watchlist
fda
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
Published: 2022-12-19 (Crawled : 10:00) - hutch-med.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.57%
H: 0.53%
C: -0.01%
treatment fda cancer submission
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
Published: 2022-11-22 (Crawled : 10:00) - biospace.com/
ARGX | $357.65 -0.21% 93K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -0.35%
fda application license review
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Published: 2022-08-11 (Crawled : 10:00) - biospace.com/
RDUS | $18.59 0.36% 77K
|
Health Technology
|
| O: 1.59%
H: 2.25%
C: -0.08%
fda elacestrant granted review cancer elascestrant her2- her2 metastatic breast cancer
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
Published: 2022-08-01 (Crawled : 10:00) - biospace.com/
ELDN | $1.82 -8.54% 320K
|
Manufacturing
|
| O: 3.32%
H: 1.61%
C: -2.57%
fda clearance kidney application
ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder
Published: 2022-07-05 (Crawled : 10:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
ant-01 fda drug positive major depressive disorder
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
Published: 2022-07-04 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
| Email alert
Add to watchlist
RLFTY | $1.4006 733.33% 100
|
n/a
| Email alert
Add to watchlist
NRXP 1 d | $3.005 -0.5% 170K
|
Manufacturing
| Email alert
Add to watchlist
covid-19 fda risk collaboration aviptadil authorization emergency use authorization
Philips Collaboration Live integrated tele-ultrasound expands FDA 510(k) clearance for remote diagnostic use to additional mobile platforms
Published: 2022-03-11 (Crawled : 10:00) - globenewswire.com
PHG | $20.0 0.1% 340K
|
Health Technology
|
| O: 1.41%
H: 0.0%
C: 0.0%
diagnostic fda clearance mobile collaboration platform tiona
NRx Pharmaceuticals Submits Emergency Use Authorization Application to US FDA for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
Published: 2022-01-05 (Crawled : 10:00) - biospace.com/
NRXP 1 d | $3.005 -0.5% 170K
|
Manufacturing
|
| O: 1.52%
H: 0.0%
C: 0.0%
covid-19 zyesami treatment fda aviptadil als risk application covid media authorization merge emergency use authorization
Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
Published: 2022-01-06 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
|
| O: 19.47%
H: 3.85%
C: -11.85%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: 2.87%
H: 0.0%
C: 0.0%
NRXP 1 d | $3.005 -0.5% 170K
|
Manufacturing
|
| O: -3.39%
H: 6.19%
C: 3.92%
covid-19 treatment fda aviptadil risk covid media submission
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
AULT | $0.2998 23.83% 53M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.